Pharmacokinetic-pharmacodynamic modeling of benznidazole and its antitrypanosomal activity in a murine model of chronic Chagas disease
PLOS Neglected Tropical Diseases · 2025
DOI: 10.1371/journal.pntd.0012968 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Neglected Tropical Diseases, 2025. Verfasst von Frauke Assmus und 12 weiteren Autor:innen. Beteiligte Einrichtung: Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Nitroimidazoles, Chagas Disease, Trypanocidal Agents, Trypanosoma cruzi. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bundesministerium für Bildung und Forschung through KfW (Germany), Foreign Commonwealth & Development Office (FCDO, UK), Directorate-General for International Cooperation (DGIS, Netherlands).
Abstract (Originalsprache)
Background There is an urgent need for improved treatments for Chagas disease, a neglected tropical infection caused by the protozoan parasite Trypanosoma cruzi . Benznidazole, the first line therapy, has severe limitations such as poor tolerability and variable efficacy in the chronic stage of infection. To optimize dosing regimens, a better understanding of the pharmacokinetic/pharmacodynamic (PK/PD) relationship for benznidazole is crucial. This study aimed to characterize the population pharmacokinetic properties of benznidazole in mice and investigate the relationship between exposure and antitrypanosomal activity in T. cruzi infected mice. Methodology/principal findings Antitrypanosomal activity was assessed in 118 BALB/c mice with chronic-stage T. cruzi infection, utilizing highly sensitive in vivo bioluminescence imaging (BLI). Benznidazole was administered at doses ranging from 10 to 100 mg/kg for 5–20 days. The pharmacokinetic properties of benznidazole were evaluated in 52 uninfected BALB/c mice using nonlinear mixed-effects modeling. The relationship between simulated benznidazole exposure and sterile parasitological cure in the BLI experiments was evaluated by logistic regression and partial least squares – discriminant analysis. Benznidazole pharmacokinetics in mice were well described by a one-compartment disposition model with first-order absorption, with higher doses associated with slower absorption. Univariate logistic regression revealed a significant correlation between drug exposure and the probability of parasitological cure. Total plasma exposure, time above IC 90 and peak plasma concentration were all strongly associated with efficacy, provided that benznidazole was administered for at least 5 days. Conclusions/significance This is the first study to successfully quantify the dose-response relationship for benznidazole in T. cruzi -infected mice using preclinical BLI data. Our results underscore the complexity of distinguishing PK/PD drivers of efficacy due to high collinearity between PK/PD index parameters, and we propose dose-fractionation studies for future research. Studying the PK/PD relationship using the BLI model provides valuable insights, aiding hypothesis generation through endpoint assessment of parasite infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
- Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
- Department of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom.
- Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry, United Kingdom.
- Centre for Drug Candidate Optimisation, Monash University, Melbourne, Australia.
- Drugs for Neglected Disease initiative, Geneva, Switzerland.
ORCID-Profile: Joel Tarning
Förderung
- Bundesministerium für Bildung und Forschung through KfW (Germany)
- Foreign Commonwealth & Development Office (FCDO, UK)
- Directorate-General for International Cooperation (DGIS, Netherlands)
- Direktion für Entwicklung und Zusammenarbeit (DEZA, Switzerland)
- Drugs for Neglected Diseases initiative (DNDi)
- Welcome Trust
- Bundesministerium für Bildung und Forschung
- Foreign, Commonwealth and Development Office
Zitieren
APA
Assmus, F., Adehin, A., Hoglund, R. M., Fortes Francisco, A., Lewis, M. D., Kelly, J. M., Charman, S. A., White, K. L., Shackleford, D. M., Escudié, F., Chatelain, E., Scandale, I., & Tarning, J. (2025). Pharmacokinetic-pharmacodynamic modeling of benznidazole and its antitrypanosomal activity in a murine model of chronic Chagas disease. PLOS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0012968
Vancouver
Assmus F, Adehin A, Hoglund RM, Fortes Francisco A, Lewis MD, Kelly JM, et al. Pharmacokinetic-pharmacodynamic modeling of benznidazole and its antitrypanosomal activity in a murine model of chronic Chagas disease. PLOS Neglected Tropical Diseases. 2025. doi:10.1371/journal.pntd.0012968
BibTeX
@article{Assmus2025,
author = {Assmus, Frauke and Adehin, Ayorinde and Hoglund, Richard M and Fortes Francisco, Amanda and Lewis, Michael D and Kelly, John M and Charman, Susan A and White, Karen L and Shackleford, David M and Escudié, Fanny and Chatelain, Eric and Scandale, Ivan and Tarning, Joel},
title = {Pharmacokinetic-pharmacodynamic modeling of benznidazole and its antitrypanosomal activity in a murine model of chronic Chagas disease},
journal = {PLOS Neglected Tropical Diseases},
year = {2025},
doi = {10.1371/journal.pntd.0012968}
}
EUVIMED